Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform

Go back to Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform

Diplomat Announces 3rd Quarter Financial Results

November 2, 2016 4:17 PM UTC

FLINT, Mich., Nov. 2, 2016 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2016.  All comparisons, unless otherwise noted, are to the quarter ended September 30, 2015.

Third Quarter 2016 Highlights include:

Revenue of $1,181 million, an increase of 25% or $234 million 12% organic revenue growth Total prescriptions dispensed of 266,000, an increase of 9% Gross margin of 6.6% versus 8.0% Gross profit per prescription dispensed of $289, compared to $301... More